These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34210138)

  • 21. Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin Inhibitors.
    Chapagai D; Merhej G; McInnes C; Wyatt MD
    ACS Chem Biol; 2023 Jul; 18(7):1642-1652. PubMed ID: 37433100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
    Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
    Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
    Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
    Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
    Lu J; Xin S; Meng H; Veldman M; Schoenfeld D; Che C; Yan R; Zhong H; Li S; Lin S
    PLoS One; 2013; 8(4):e53317. PubMed ID: 23658603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models.
    Gunasekaran P; Yim MS; Ahn M; Soung NK; Park JE; Kim J; Bang G; Shin SC; Choi J; Kim M; Kim HN; Lee YH; Chung YH; Lee K; EunKyeong Kim E; Jeon YH; Kim MJ; Lee KR; Kim BY; Lee KS; Ryu EK; Bang JK
    J Med Chem; 2020 Dec; 63(23):14905-14920. PubMed ID: 33142063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
    Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
    Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer.
    Kim TG; Lee JH; Lee MY; Kim KU; Lee JH; Park CH; Lee BH; Oh KS
    Biol Pharm Bull; 2017; 40(9):1454-1462. PubMed ID: 28867728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
    McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
    Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
    Yan F; Liu G; Chen T; Fu X; Niu MM
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells.
    Rubner S; Schubert S; Berg T
    Org Biomol Chem; 2019 Mar; 17(12):3113-3117. PubMed ID: 30848278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain.
    Rubner S; Scharow A; Schubert S; Berg T
    Angew Chem Int Ed Engl; 2018 Dec; 57(52):17043-17047. PubMed ID: 30351497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
    Yun T; Qin T; Liu Y; Lai L
    Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
    Zhao XZ; Hymel D; Burke TR
    Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.